Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials.
Ariel IzcovichReed Alexander Cunningham SiemieniukJessica Julia BartoszkoLong GeDena ZeraatkarElena KumAnila QasimAssem M KhamisBram RochwergThomas AgoritsasDerek K ChuShelley L McLeodReem A MustafaPer VandvikRomina Brignardello-PetersenPublished in: BMJ open (2022)
Hydroxychloroquine probably increases the risk of diarrhoea and nausea and/or vomiting and may increase the risk of cardiac toxicity and cognitive dysfunction/delirium. Lopinavir/ritonavir may increase the risk of diarrhoea and nausea and/or vomiting. Remdesivir may have no important effect on risk of acute kidney injury or cognitive dysfunction/delirium. These findings provide important information to support the development of evidence-based management strategies for patients with COVID-19.
Keyphrases
- chemotherapy induced
- cardiac surgery
- acute kidney injury
- systematic review
- irritable bowel syndrome
- coronavirus disease
- sars cov
- clinical trial
- meta analyses
- hip fracture
- antiretroviral therapy
- open label
- left ventricular
- oxidative stress
- study protocol
- double blind
- randomized controlled trial
- healthcare
- health information
- atrial fibrillation
- abdominal pain